Sex differences in brain frailty measures and outcomes after endovascular thrombectomy: ESCAPE-NA1 analysis.

J Neurol SciJun 24, 2026 (epub)
Clinical ResearchNeurologyEmergency Medicine

Satoru Fujiwara, Joachim Fladt, Faysal Benali et al.

✦ AI-curated · Sources linked

In 30 seconds

This post-hoc analysis of the ESCAPE-NA1 randomized trial examined sex differences in brain frailty markers and their association with 90-day outcomes after endovascular thrombectomy (EVT) in 1102 patients. While no significant sex interactions were found, women showed a lower likelihood of achieving functional independence (mRS 0-2) associated with cortical atrophy (adjusted OR 0.54) compared to men.

Key findings

  • Cortical atrophy was associated with a lower likelihood of achieving mRS 0-2 in women (adjusted OR 0.54).
  • No clear associations between brain frailty markers and outcomes were observed in men.
  • Exploratory analyses indicated that several brain frailty markers impacted women more than men regarding functional independence.

Why it matters

Understanding the impact of brain frailty on outcomes after EVT is crucial for optimizing patient management. This study highlights potential sex differences that may influence recovery, emphasizing the need for tailored approaches in treatment and prognosis.

Source

PubMed · PMID 42349084

Published in J Neurol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.